ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 267 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,199,387 | -35.1% | 267,934 | -13.9% | 0.02% | -32.1% |
| Q2 2023 | $11,091,686 | +383.6% | 311,040 | +244.5% | 0.03% | +300.0% |
| Q1 2023 | $2,293,620 | +305.5% | 90,300 | +547.5% | 0.01% | +250.0% |
| Q4 2022 | $565,609 | -62.5% | 13,945 | -67.5% | 0.00% | -60.0% |
| Q2 2022 | $1,510,000 | +395.1% | 42,886 | +546.9% | 0.01% | +400.0% |
| Q1 2022 | $305,000 | -95.0% | 6,629 | -91.1% | 0.00% | -92.9% |
| Q2 2021 | $6,145,000 | +78.7% | 74,200 | +43.1% | 0.01% | +55.6% |
| Q1 2021 | $3,439,000 | +150.5% | 51,862 | +63.2% | 0.01% | +28.6% |
| Q2 2020 | $1,373,000 | -91.7% | 31,787 | -94.4% | 0.01% | -94.8% |
| Q1 2020 | $16,468,000 | +65.9% | 572,403 | +265.9% | 0.13% | +346.7% |
| Q4 2019 | $9,924,000 | +120.1% | 156,451 | -33.5% | 0.03% | +150.0% |
| Q3 2018 | $4,509,000 | +76.0% | 235,216 | +24.9% | 0.01% | +50.0% |
| Q2 2018 | $2,562,000 | +1654.8% | 188,364 | +374.2% | 0.01% | – |
| Q4 2017 | $146,000 | – | 39,726 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |